Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPPLE-R: Ipilimumab, Nivolumab, Tocilizumab + Radiation in Pancreatic Cancer
NCT04258150Phase 2Terminated
- Sponsor
- Herlev Hospital
- Start
- Apr 2020
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in pancreatic cancer (PC), sponsored by Herlev Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Apr 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04258150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258150.